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Abstract
Background: Only a subset of radically resected pancreatic ductal adenocarcinoma (PDAC) patients benefit from
chemotherapy, and identification of prognostic factors is warranted. Recently miRNAs emerged as diagnostic biomarkers
and innovative therapeutic targets, while high-throughput arrays are opening new opportunities to evaluate whether they
can predict clinical outcome. The present study evaluated whether comprehensive miRNA expression profiling correlated
with overall survival (OS) in resected PDAC patients.
Methodology/Principal Findings: High-resolution miRNA profiles were obtained with the Toray’s 3D-GeneTM-miRNA-chip,
detecting more than 1200 human miRNAs. RNA was successfully isolated from paraffin-embedded primary tumors of 19 out
of 26 stage-pT3N1 homogeneously treated patients (adjuvant gemcitabine 1000 mg/m2/day, days-1/8/15, every 28days),
carefully selected according to their outcome (OS,12 (N= 13) vs. OS.30 months (N= 6), i.e. short/long-OS). Highly
stringent statistics included t-test, distance matrix with Spearman-ranked correlation, and iterative approaches.
Unsupervised hierarchical analysis revealed that PDACs clustered according to their short/long-OS classification, while
the feature selection algorithm RELIEF identified the top 4 discriminating miRNAs between the two groups. These miRNAs
target more than 1500 transcripts, including 169 targeted by two or more. MiR-211 emerged as the best discriminating
miRNA, with significantly higher expression in long- vs. short-OS patients. The expression of this miRNA was subsequently
assessed by quantitative-PCR in an independent cohort of laser-microdissected PDACs from 60 resected patients treated
with the same gemcitabine regimen. Patients with low miR-211 expression according to median value had a significantly
shorter median OS (14.8, 95%CI = 13.1–16.5, vs. 25.7 months, 95%CI = 16.2–35.1, log-rank-P = 0.004). Multivariate analysis
demonstrated that low miR-211 expression was an independent factor of poor prognosis (hazard ratio 2.3, P = 0.03) after
adjusting for all the factors influencing outcome.
Conclusions/Significance: Through comprehensive microarray analysis and PCR validation we identified miR-211 as a
prognostic factor in resected PDAC. These results prompt further prospective studies and research on the biological role of
miR-211 in PDAC.
Citation: Giovannetti E, van der Velde A, Funel N, Vasile E, Perrone V, et al. (2012) High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic Role of
MiR-211 in Pancreatic Cancer. PLoS ONE 7(11): e49145. doi:10.1371/journal.pone.0049145
Editor: Nathan A. Ellis, University of Illinois at Chicago, United States of America
Received July 3, 2012; Accepted October 4, 2012; Published November 14, 2012
Copyright:  2012 Giovannetti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have declared that no competing interests exist. This work was partially supported by grants from Netherlands Organization for Scientific
Research, VENI grant (project number 91611046 (Elisa Giovannetti)) and Stimuleringfonds Open Access (Elisa Giovannetti), CCA-VICI Foundation grant (Elisa
Giovannetti, Amir Avan, Godefridus J Peters), AIRC Marie Curie International Fellowship (Elisa Giovannetti), and Italian Minister of Research, PRIN-2009 (Elisa
Giovannetti, Niccola Funel, Ugo Boggi). Toray Industries, Inc. is a funder due to employment of Hiroko Sudo, who provided technical support to conduct this
project, but did not have a role in study design. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist. In this study, the authors use products of Toray Industries, Inc., 3D-
GeneTM’’ for the miRNA microarray, but this does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: elisa.giovannetti@gmail.com
. These authors contributed equally to this work.
Introduction
With a 5-year survival rate of less than 5%, pancreatic ductal
adenocarcinoma (PDAC), including more than 90% of pancreatic
cancers, is the most lethal among the major solid tumors [1]. In
recent years, there have been important advances in the
understanding of molecular biology of pancreatic cancer, as well
as in diagnosis and staging. However, minimal progress has been
achieved in prevention, early diagnosis, treatment and outcomes
[2].
Surgical resection is the only curative modality for PDAC, but
only 15–20% of patients have resectable disease at the time of
diagnosis. Nevertheless, the prognosis of patients after complete
resection is poor, with 3-year disease-free survival (DFS) rate at
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27% (95% confidence interval (CI): 23–32%) and median overall
survival (OS) of 15–19 months [3].
Only a subset of radically resected PDAC patients benefit from
chemotherapy, and adjuvant treatments can have substantial
toxicities [4]. Therefore, novel biomarkers of sensitivity to
adjuvant therapy are urgently warranted in order to individualize
clinical management and improve therapeutic outcome [5].
Extensive studies have characterized the complex genetic
networks and transcriptomics alterations underlying the develop-
ment and progression of PDAC [6]. The recent discovery of
microRNAs (miRNAs) has provided additional insights potentially
explaining the gap that exists between tumor genotype and
phenotype.
MiRNA are a class of small non-coding evolutionarily
conserved RNAs [19–23 nucleotides] that have been found in
animal and plant cells. As of today, 1921 unique mature human
miRNAs are listed in the miRBase database (Release 18,
November 2011) [7]. MicroRNA genes are transcribed as non-
coding transcripts, and are processed through a series of sequential
steps involving the RNase III enzymes, Drosha and Dicer. The
processed microRNAs are finally incorporated into the RNA-
induced silencing complex (RISC) to direct this complex to down-
regulate gene expression via binding to the 39UTR of the target
mRNAs. Plant and some animal miRNAs form perfect base pairs
with their target mRNAs, resulting in their degradation. However,
most of the human miRNAs bind to their target 39UTRs with
imperfect complementarities and therefore induce translational
repression [8].
The pivotal regulatory role of each miRNA in controlling
expression of multiple gene transcripts offers a unique opportunity
of identifying critical miRNAs as informative biomarkers for
detection, diagnosis and prognosis of tumors that result from
deregulation of multiple genes [9]. This underlying biological
mechanism was most likely the reason why expression patterns of
217 miRNAs were found to classify cancer types more accurately
than the information based on expression profile of ,16000
mRNAs [10].
The role of miRNAs in the control of proliferation/differenti-
ation and apoptosis, and their aberrant expression in many
tumors, indicated that they might function as tumor suppressors
and oncogenes, suggesting their use for diagnostic and therapeutic
purposes. Furthermore, selected miRNAs may influence tumor
malignant behavior and response to chemotherapy [11].
Our previous studies focusing on miR-21 showed that both
Caucasian and Asian patients harboring high expression of this
miRNA in their PDAC specimens had a significantly shorter
survival [12,13]. This miRNA has been referred to as an
‘‘oncomir’’ (i.e. a miRNA with oncogenic properties) because it
is almost omnipresent and overexpressed in human tumors.
Recent in vivo studies in miR-21 overexpressing mice model
established by Cre/Tet-off technologies, demonstrated its onco-
genic role, showing its significant impact on tumor initiation,
maintenance, survival and invasion [14].
However, high-throughput technological innovations in detect-
ing hundreds of microRNAs provide new effective ways to unravel
the role of other key miRNAs regulating multiple genes that might
explain why patients with similar clinicopathological characteris-
tics can have considerable variation in clinical outcomes.
Therefore, in the present study we evaluated whether compre-
hensive miRNA expression profiling, using a miRNA chip
detecting more than 1200 types of human miRNA, can distinguish
between PDAC patients with very short OS compared to long-
term survivors.
In particular, we carefully selected 26 PDAC patients with
homogeneous clinicopathological characteristics who underwent
resection with curative intent and were treated with three cycles of
standard gemcitabine adjuvant regimen. Half of these patients had
a dismal prognosis, dying within 1 year of diagnosis, whereas the
other 13 patients survived more than 30 months. The miRNA
microarray analysis was performed in 19 samples that passed the
RNA quality criterion, including 13 patients with short survival
and 6 patients with long survival. Since miR-211 expression status
emerged as the most predictive biomarker for treatment outcome
in these patients, further analysis of miR-211 expression was
performed in a second cohort of 60 patients, all treated with the
same adjuvant therapy. This independent set confirmed the
significant association of miR-211 expression status with both OS
and DFS.
Methods
Patients
Patients who underwent radical surgical resection with curative
intent (pancreatico-duodenectomy, total pancreatectomy and
distal pancreatectomy) at the Department of General Surgery
and Transplant, University Hospital of Pisa (Pisa, Italy), between
2000 and 2010 were retrospectively reviewed using electronic
medical records. Among them, for the high-resolution miRNA
expression profiling we selected 26 patients with similar patholog-
ical findings, clinical characteristics, and treatment but consider-
able variation in clinical outcomes. In particular, half of these
patients had an extremely poor prognosis, dying within 1 year of
diagnosis and were classified as ‘‘short-OS’’, whereas the other 13
patients survived more than 30 months, and were classified as
‘‘long-OS’’. The characteristics of these 2 groups are reported in
Table 1.
The validation cohort was composed of other 60 radically
resected PDAC patients diagnosed and treated in the same period,
with their characteristics also described in the Table 1. All these
patients underwent gemcitabine-based adjuvant treatment, as
described previously [15].
Ethics
All the patients gave their written informed consent to the
sample collection and analysis, and the study has received
approval from the Ethics committee of Pisa University Hospital
as a follow-up study of the research protocol entitled ‘‘Pharma-
cogenetics of gemcitabine-related genes in pancreas cancer:
correlation with clinical outcome and tolerability’’ [15]. The
responsible investigators ensure that this study was conducted
according to the Declaration of Helsinki, the European Guidelines
on Good Clinical Practice, and relevant national and regional
authority requirements.
Tissues
Formalin Fixed Paraffin Embedded (FFPE) sections were
carefully reviewed for diagnosis and tumor content. Because of
the long experience of our pathology laboratory on large cohorts
of radically resected PDAC patients, there was no difficulty in
selecting areas with morphological defined cancer cells [16]. The
tumors were classified and evaluated for tumor staging and
grading as proposed by the WHO, as reported in Table 1.
RNA extraction from FFPE slides
Histological sections (10 mm) were prepared from each FFPE
specimen. Paraffin was removed by xylene treatment and tissues
were washed with ethanol twice to remove xylene. Tissues were
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then treated with proteinase K at 37uC overnight. Following
centrifugation, the supernatant was processed with a silica-based
spin column (New Frontiers Research Laboratories, Toray
Industries Inc., Kanagawa, Japan) in order to obtain purified
total RNA. The degrees of RNA cross-linking and RNA
degradation were analyzed by electrophoresis using an Agilent
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
The samples that showed the majority of RNAs at .4,000
nucleotides due to cross-linking, or the majority of RNAs at
,1,000 nucleotides due to degradation in the electrophoresis
patterns were unsuitable for the miRNA analysis and thus not
used. Of the 26 studied samples, 19 samples passed this criterion
and were used in the miRNA profiling.
For the 60 samples used as an independent validation set, a
mean of 5000 neoplastic cells were then dissected using the Leica
LMD6500 instrument (Leica, Wetzlar, Germany), as described
previously [17]. The precision of the narrow focus of the laser
beam resulted in the capture of individual cells with high degree of
accuracy (Figure S1). RNA was successfully isolated using the
RecoverAll Total Nucleic Acid Isolation kit (Ambion, Applied
Biosystems, Foster City, CA, USA), according to the manufactur-
er’s instructions. RNA yields and purity were checked at 260 and
280 nm with NanoDropH-1000 Detector (NanoDrop-Technolo-
gies, Wilmington, USA).
MiRNA profiling
We utilized Toray’s 3D-GeneTM (Toray Industries, Japan)
human microRNA chips for miRNA expression profiling. The
reproducibility and comparability to Taqman RT-PCR, and the
experimental procedures of Toray’s microarray, were described
previously [18,19]. Briefly, 500 ng total RNA extracted from
FFPE section was analyzed for miRNA profiling using microarray,
3D-GeneH miRNA oligo chip v.16 (Toray Industries) according to
the manufacturer’s protocol vE1.10. The number of mounted
miRNAs on this microarray is 1212 in total. Microarray was
scanned and the obtained images were numerated using 3D-
Table 1. Clinical characteristics of the PDAC patients.
Characteristic Patients for the miRNA profiling n (%)
Patients of the validation
cohort n (%)
Short-OS Long-OS
No. Patients 13 13 60
Age. median [range] 64 (37–71) 63 (56–79)
#65 8 (61.5) 6 (46.2) 36 (60.0)
.65 5 (38.5) 7 (53.8) 24 (40.0)
Sex
Male 7 (53.8) 3 (23.1) 28 (46.7)
Female 6 (46.2) 10 (76.9) 32 (53.3)
Operation procedure
pancreatico-duodenectomy 11 (84.6) 9 (69.2) 46 (76.7)
total pancreatectomy 0 (0.0) 0 (0.0) 3 (5.0)
distal pancreatectomy 2 (15.4) 4 (30.8) 11 (18.3)
TNM Stage
pT3 N0 Mx 0 (0.0) 1 (7.7) 0 (0.0)
pT3 N1 Mx 13 (100.0) 12 (92.3) 60 (100.0)
Nodal status
N0 0 (0.0) 1 (7.7) 0 (0.0)
N1 13 (100.0) 12 (92.3) 60 (100.0)
Grading
G1 0 (0.0) 0 (0.0) 3 (5.00)
G2 8 (61.5) 9 (69.2) 27 (45.0)
G3 5 (38.5) 4 (30.8) 30 (50.0)
Unknown 0 (0.0) 0 (0.0) 0 (0.0)
Resection margins
R0 12 (92.2) 12 (92.2) 54 (90.0)
R1 1 (7.8) 1 (7.8) 6 (10.0)
Vascular invasion
Yes 4 (30.8) 3 (23.1) 23 (38.3)
No 9 (69.2) 10 (76.9) 37 (31.7)
Perineural invasion
Yes 7 (53.8) 9 (69.2) 31 (51.7)
No 6 (46.2) 4 (30.8) 29 (48.3)
doi:10.1371/journal.pone.0049145.t001
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GeneH scanner 3000 (Toray Industries). The expression level of
each miRNA was globally normalized using the background-
subtracted signal intensity of the entire miRNAs in each
microarray (Description S1).
All microarray data from this study are in agreement with
Minimum Information About a Microarray Experiment (MIAME)
and publicly available through the NCBI’s Gene Expression
Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/
projects/geo/) under the series record GSE38781.
Overall clustering
To explore differences in expression patterns between the two
groups of samples, we selected miRNAs that showed a significant
difference in expression. The t-test was performed on the long-OS
and short-OS groups for all miRNAs and the ones that did not
appear to be significantly different (p.0.05) have been filtered out.
Hierarchical unsupervised cluster analysis was performed on the
remaining 170 miRNAs. Two-tailed Spearman ranked correlation
was used to generate a distance matrix. Subsequently the distance
matrix was used to generate clusters for both miRNAs and samples
using a hierarchical clustering algorithm, based on average linkage
[20–21].
Analysis with RELIEF and iterative RELIEF
A feature selection algorithm, RELIEF [22–24], was employed
on the complete data set in order to discover the most
discriminating miRNAs. RELIEF is an iterative algorithm that
assigns weights to features (i.e., miRNA expression values)
according to distances between features within and among groups.
Out of the 1212 miRs, 703 miRs that have a maximum of one
missing value over all samples were selected. The RELIEF
algorithm was applied in order to select the top 10 highest
weighing miRNAs. In a following analysis we generated 100
random sets of 6 out of 13 samples classified as short. On each
random set of samples, combined with the 6 samples classified as
long the RELIEF algorithm was applied to select the top 10
highest weighing miRs. For all miRNAs appearing in the top 10 a
score was kept and the top 10 most appearing miRNAs were
selected.
Top miRNAs target genes
A search was performed on the predicted targets for the most
discriminating miRNAs identified in our study using the TargetScan
web interface v.6.1 (http://www.targetscan.org/) and miRDB
version 4.0 (http://mirdb.org/miRDB/index.html). Following
comparison of all datasets, a subset of genes that were targeted
by more than one miRNA was generated.
Reverse transcription (RT) and quantitative-PCR analysis
of miR-211 and miR-4321
In order to validate the findings of the microarray analysis, we
evaluated the expression of the most discriminating miRNA, miR-
211, as well as of the rarely investigated miR-4321, in an
independent cohort of PDAC patients. RNA (10–100 ng) was
reverse transcribed and the resulting cDNA was amplified using
the specific custom TaqManH-MicroRNA-assays (Applied Biosys-
tems) for miR-211 and miR-4321. We performed a preliminary
analysis of 3 endogenous controls (RNU1, RNU6 and RNU43) in
a series of 10 PDAC cells. Since the values of RNU6 were the
closest to the geometric mean values of these genes, we used this
housekeeping for the normalization of all the following analysis.
The PCR reactions were performed in the 7500HT sequence
detection system (Applied Biosystems), in accordance with the
manufacturer’s instructions. Specimens were amplified in dupli-
cate with appropriate non-template controls. Amplification data
were normalized to RNU6 expression. Quantification of relative
expression (reported as arbitrary units [a.u.]) was performed using
the DCt method. Quantitative-PCR data showed a variability
coefficient of Ct always lower than 2% of mean values.
Correlation of miR-211 and miR-4321 with outcome
Comparison of clinical information and miRNA expression
levels were made using Pearson x2 test and Wilcoxon test. The
relationship between miRNA expression and outcome was
evaluated by stratifying the patients with respect to the median
expression value (high versus low expression). The analyses of the
samples were done in a blinded fashion relative to clinical
outcome.
OS was calculated from the date of surgery to the date of death,
DFS was defined as the time from the date of surgery to the date of
first relapse or death. Survival curves were constructed using the
Kaplan-Meier method, and differences were analyzed using log-
rank test. The significant prognostic variables of OS and DFS in
univariate analysis were included in multivariate analyses, using
Cox’s proportional hazards model.
The relationship between miR-211 expression and outcome was
also evaluated by means of the unsupervised clustering algorithm
k-means. This algorithm partitions data points into k groups in an
iterative fashion, given a predefined number of clusters k (k = 2,
maximum iterations = 1000).
For the Pearson x2 test, Wilcoxon-test, Kaplan-Meier curves,
log-rank test and multivariate analysis, data were analyzed using
SPSS v.17 statistical software (SPSS, Inc, Chicago, IL), while all the
other computational analyses were performed in R (R v.2.10.1,
packages: stats, dprep). Further details on methods and statistics
are provided in the Supplemental data.
In vitro studies
The human PDAC cell lines AsPc-1, Capan-1, CFPAC-1,
HPAC, HPAF-II, MIA PaCa-2, PANC-1, PL45, and Su86.86
were purchased from the American Type Culture Collection
(ATCC, Manassas, VA), while five primary cell cultures (LPc006,
LPc028, LPc033, LPc067, and LPc111) were isolated from
patients at the University Hospital of Pisa (Pisa, Italy), as described
previously (17). The cells were cultured in RPMI-1640 media,
supplemented with 10% FBS, and 1% penicillin (50 IU/mL) and
streptomycin (50 mg/mL) (Gibco, Gaithersburg, MD). Cells were
kept at 37uC under an atmosphere of 5% CO2 in 75 cm
2 tissue
culture flasks (Greiner Bio-One GmbH, Frickenhausen, Germany)
and harvested with trypsin-EDTA in their exponentially growing
phase. RNA was extracted using a Trizol-chloroform protocol
(Sigma, St. Louis, MO). RNA yields and purity were checked by
measuring optical density at 260/280 nm with a NanodropH
spectrophotometer. The basal expression of miR-211 was assessed
by qRT-PCR, as described above for PDAC tissues. Amplification
data were normalized to RNU6 expression, and quantification of
relative expression was performed using the DCt method.
The effect of miR-211 on chemosensitivity was evaluated in the
MIA PaCa-2 and LPc028 cells, by transfecting these cells with the
precursor and antisense oligonucleotides (pre-miR-211 and anti-
miR-211) purchased from Ambion-Applied Biosystems (Assay ID,
MC10168 and MH10168, respectively) at 30 nM final concen-
tration. Cells were plated at 5,000 cells/well in 200 ml RPMI with
10% FBS and 1% antibiotics. After 24 hours cells were exposed to
0.9 ml oligofectamine (Invitrogen, Paisley, UK) in serum-free
medium, mixed for 10 minutes at room temperature, followed by
the addition of 0.3 ml of 6.25 mM miR-211 precursor or inhibitor.
High-Throughput MiRNAs Array in Pancreatic Cancer
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Cells were also incubated with miRNA negative controls
(Ambion). After overnight exposure the medium was removed
from the wells and replaced with RPMI with 10% FBS, without
antibiotics. Then cells were allowed to grow for additional
48 hours in drug-free medium or treated with 1 mM gemcitabine,
as described above. Additional control wells were used for RNA
extraction, to evaluate the transfection efficiency.
Finally, in preliminary functional analyses on potential targets of
miR-211 predicted by TargetScan, we selected ribonucleotide
reductase subunit 2 (RRM2), which is an important cellular target
of gemcitabine [25]. Therefore, we performed a RT-PCR analysis
of the expression of RRM2 in the cells transfected with pre-miR-
211 and anti-miR-211, as described above. These PCR reactions
were performed with primers and probe from the Applied
Biosystems Assay-on-Demand Gene expression product
Hs0035724, using a previously validated method [15]. Amplifica-
tions were normalized to GAPDH, and quantitation of gene
expression was performed using the DDCT calculation, where CT
is the threshold cycle; the amount of target gene, normalized to
GAPDH and relative to the calibrator (untreated control cells), is
given as 22DDCT. Specimens were amplified in triplicate with
appropriate non-template controls, and the coefficient of variation
was ,1% for all replicates.
Results
Characteristics of the patients
Table 1 summarizes the clinicopathological characteristics of all
the PDAC patients evaluated in the present study. Most patients
had stage-T3 grade-2 tumors, with positive lymph nodes, and
perineural invasion.
The miRNA microarray analysis was performed in 19 samples
that passed the RNA quality criterion. These patients included 13
patients with OS shorter than 1 year (median OS, 8.0, 95% CI,
5.4–10.6) and 6 patients who survived more than 30 months
(median OS, 31.0, 95% CI, 30.6–31.4). The Kaplan-Meier plots
of these groups are reported in the Figure S2.
A further group of 60 patients was used as a validation cohort,
with median OS and DFS of 20.9 and 11.9 months, respectively
(See Figure S3 for the Kaplan-Meier plots). The event-rate was
66.7%, and the median follow-up for surviving patients was 21.4
months. In this cohort OS was significantly longer (p = 0.009) for
patients harbouring grade 1/2 tumors (median OS, 25.2, 95%CI,
14.7–35.7) than patients with grade 3 PDACs (median OS, 14.8,
95%CI, 11.3–18.3) Data on outcomes according to patients’
characteristics are reported in Table S1.
MiRNA microarray analysis: overall clustering
After the analytical procedures for the normalization of the raw
data from the microarray analysis (described in Description S1) we
performed a t-test analysis, which resulted in a list of 170 miRNAs
that show significant differences in expression between the two
groups (p,0.05) (Table S2). In order to perform hierarchical
cluster analysis we subsequently constructed a distance matrix
using the two-tailed Spearman correlation test, due to the non-
normal distribution of expression within samples. This cluster
analysis showed a good separation between the two groups of
samples (short-OS vs. long-OS), based on the significantly different
miRNAs (Figure 1).
MiRNA microarray analysis: RELIEF and iterative RELIEF
The RELIEF algorithm was employed on the complete data set,
as decribed in the methods. This algorithm assigned scores to each
miRNA according to how well it discriminated the two groups of
samples (e.g., samples from short-OS versus samples from long-OS
patients). This resulted in a top 10 of most discriminating
miRNAs. Figure S3 shows the cluster analysis based on those 10
miRNAs, whilst Table 2 shows this group of top 10 miRNAs and
their assigned scores.
After observing how the scores were distributed (Figure S4), we
selected the first four (miR-211, miR-4321, miR-1207-3p and
miR-326) among this top 10 and performed a cluster analysis.
As shown in the Figure 2, this top 4 miRNAs clearly separated
the two groups of patients. With the exception of one case (S2),
which showed very high expression values for all the studied
miRNAs, the two main clusters on the x-axis correspond to the
two groups (short/long-OS). In particular, since the colors in the
Figure 1. Heatmap of the clustering of 170 miRs filtered based
on t-test p-value,0.05. In order to perform hierarchical cluster
analysis we constructed a distance matrix using the two-tailed
Spearman correlation test, due to the non-normal distribution of
expression within samples. The cluster analysis shows a good
separation between the two groups of samples, based on the
significantly different miRNAs. The microRNA expression data were
centered by 2 directions (i.e., by miRNA and patients). Red and yellow
represent low and high miRNA expression, respectively.
doi:10.1371/journal.pone.0049145.g001
Table 2. Top-10 most discriminative miRNAs, based on
RELIEF score.
Number miRNA RELIEF score Iterative score
1 miR-211 0.372 86
2 miR-4321 0.332 76
3 miR-1207-3p 0.330 81
4 miR-326 0.321 78
5 miR-1914* 0.297 53
6 miR-3610 0.269 32
7 miR-197 0.260 7
8 let-7b* 0.253 43
9 miR-1296 0.250 29
10 miR-4290 0.248 34
doi:10.1371/journal.pone.0049145.t002
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heatmap showed the relative expression of the miRNA across all
samples, we observed two types of expression profiles, one in
which the expression was lower in the patients with a short-OS (for
miR-211, miR-1207-3p, miR-326) and one in which the pattern
was opposite (for miR-4321). Conversely, patients with long-OS
had higher expression values for miR-211, miR-1207-3p, miR-
326, and lower expression values for miR-4321.
In order to confirm the most discriminative miRNAs we
performed an additional analysis using iterative RELIEF. As
observed from Table S3, the top 10 miRs were the same, except
for miR-1200 and miR-766 that replaced miR-197 and miR-1296.
However, the ranking of the iterative RELIEF scores showed a
clearer separation between the top 4 and the bottom 6 most
discriminative miRNAs (Figure S6). In this way we demonstrated
that the top 4 miRNAs were not biased towards any specific
sample. As reported in the Table 2, the miRNAs that appeared in
the top 4 using the RELIEF approach also appeared in the top 4
in the iterative RELIEF analysis, suggesting that the expression
profile of those 4 miRNAs can be used to confidently distinguish
between the patients with short-OS and the patients with long-OS.
Target prediction for the top miRNA candidates
The identity, chromosomal location and number of target genes
of the miRNA candidates identified in our study are summarized
in Table 3. To gain further insights into the biological pathways
potentially regulated by miRNAs, we next performed a compre-
hensive comparison between the predicted target genes for our top
4 miRNA candidates according to TargetScan and miRDB.
Importantly, in the TargetScan prediction about 10% of these
genes were predicted to be targeted by 2 miRNAs, with 13 genes
targeted by three miRNA and one gene targeted by all the four
different miRNAs (Table S4).
Analysis of the prognostic role of miR-211 and miR-4321
in an independent cohort of PDAC patients
RT-PCR analysis of miR-211 expression in 60 independent
PDAC samples was used to validate the prognostic significance of
this miRNA. This validation group did not differ significantly in
terms of clinicopathological characteristics compared to the initial
cohort of patients (Table 1).
The expression of miR-211 was detectable in all these samples,
and patients were initially categorized according to the median
expression value of miR-211 (12.8 a.u.), according to the Gaussian
distribution of the expression values, as described in the Figure S7.
Remarkably, miR-211 expression differed significantly between
grade 1/2 (N=30) and grade 3 (N= 30) tumors (P = 0.006 in the
Wilcoxon-rank-sum-test). In contrast, no difference was detected
in miR-21 expression levels according to other clinicopathological
parameters (Table S5).
A strong correlation of miR-211 expression status and clinical
outcome was demonstrated. The high miR-211 expression group
had a better prognosis than the low expression group. Patients
with miR-211 expression below median (low miR-211) had a
significantly shorter median OS (14.8 months, 95%CI, 13.1–16.5
months) compared to patients with miR-211 expression higher
than median (median OS, 25.7 months, 95%CI, 16.2–35.6
months, HR=3.0, 95%CI, 2.1–8.9, P,0.001). Similar results
were obtained with the DFS curves of patients with miR-211
expression above median, with a median DFS of 16.7, compared
to 9.3 months in patients with the lowest miR-211 expression
(P= 0.004). The OS and DFS Kaplan-Meier curves are shown in
the Figures 3A–B.
Conversely, the expression of miR-4231 was not correlated to
outcome in the same cohort of patients (Figure S8). Patients with
miR-4231 expression below median had only a trend towards a
significant longer median OS compared to patients with miR-4231
expression above median (25.8 months, 95%CI, 18.2–32.3
months, vs. 16.7 months, 95%CI, 13.7–19.7 months, P = 0.194).
Similarly, no significant differences were observed for median DFS
(13.0 months, 95%CI, 8.4–17.6 months, vs. 10.0 months, 95%CI,
2.0–17.9 months, P = 0.581).
However, given the fact that there was a good correlation
between the expression of miR-211 and OS, as shown in the
Figure S8 (r = 0.724) we further analyzed the miR-211 expression
data using K-means clustering (k = 2). Each of the 60 samples was
assigned to one of two clusters (Figure S9), which were compared
with the Kaplan-Meier curves for OS and DFS. These analyses
showed a significant difference (Figures 3C–D). The median OS of
cluster#2 was 31.0 months, 95%CI, 20.0–41.8 months, while
median OS of cluster#1 was 14.8 months, 95%CI, 13.3–16.3
months (HR=3.7, 95%CI, 2.4–9.9, P,0.001). Similarly, the
median DFS of cluster#2 was 21.5 months (95%CI, 10.0–33.1
months), while median OS of cluster#1 was 9.8 months (95%CI,
6.5–13.1 months, HR=2.4, 95%CI, 1.4–2.9, P = 0.002).
To evaluate the risk of disease progression and death we carried
out two Cox regression analyses entering all the variables
significantly associated with DFS and OS from the univariate
model. For the expression values of miR-211, these analyses were
performed categorizing patients with the median-value and the K-
means clustering.
The Cox proportional hazards regression model used for the
multivariate analysis confirmed the prognostic significance of miR-
211 expression and grading (Table 4). In particular, low miR-211
expression was significantly associated with an increased risk of
death (HR=2.0, 95%CI, 1.1–4.1, P= 0.04) as well with an
increased risk of progression (HR=2.1, 95%CI, 1.1–4.1,
P= 0.02). The multivariate analysis performed with miR-211
clusters confirmed also these data as independently prognostic for
both mortality and disease progression (Table 4).
Figure 2. Cluster analysis based on the top 4 most discrimina-
tive miRNAs performed with the RELIEF algorithm. The colors
are normalized and can only be compared left to right.
doi:10.1371/journal.pone.0049145.g002
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Analysis of miR-211 in PDAC cells
The expression of miR-211 was detectable in all the PDAC cell
lines and primary tumor cell cultures, ranging from 35.6 in Capan-
1 cells to 0.9 a.u. in the PL45 cells (Figure 4A). Of note, miR-211
expression in the 5 primary tumor cells and their originator tumors
showed a similar pattern and were highly correlated with
Spearman analysis (R2 = 0.96, P= 0.01). MIA PaCa-2 and
LPc028 cells were selected for further studies because they were
representative of cells with very low and very high expression of
miR-211, respectively. Transfection efficiency of pre-miR-211 and
anti-miR-211 was evaluated by PCR analysis, 24 hours post
transfection, showing a significant modulation of miR-211
expression in both cellular models (Figure 4B). In order to
evaluate the modulation of gemcitabine anti-proliferative effects,
we studied whether treatment with gemcitabine in pre-miR-211 or
anti-miR-211 transfected would result in increased/reduced
Table 3. Identity, chromosomal localization, and number of the predicted target gens of the top-4 most discriminative miRNAs, as
predicted with TargetScan and miRDB.
Number miRNA Chromosome miRDB targets* TargetScan targets**
1 miR-211 15q13.3 702 669
2 miR-1207-3p 8q24.21 217 488
3 miR-326 11q13.4 309 441
4 miR-4321 chr19:2250638–2250717u 14 161
Notes:
*miRDB, release January, 2012;
**TargetScan, release March 2012;
uCoordinates from the Genome Reference Consortium Human genome build 37 (GRCh37).
doi:10.1371/journal.pone.0049145.t003
Figure 3. Kaplan-Meier curves for OS and DFS according to (A–B) miR-211 above and below median expression (e.g., low vs. high
expression), and to (C–D) k-means clustering.
doi:10.1371/journal.pone.0049145.g003
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sensitivity compared to cells transfected with miRNA negative
controls as well as to cells transfected with miRNA negative
controls that were not treated with gemcitabine. As shown in
Figure 4C the transfection with pre-miR-211 led to an increased
activity of gemcitabine, with a significant reduction of the
percentages of cell growth (from 42 to 24% in MIA PaCa-2 cells
and from 31 to 18% in LPc028 cells) with respect to cells
transfected with miRNA negative controls. Conversely, the
transfection with anti-miR-211 caused a significant reduction of
the activity of gemcitabine.
Furthermore, we assessed by qRT-PCR if the expression of
RRM2 was modulated in the transfected cells, showing its
significant reduction in cells with increased expression of miR-
211. On the contrary, we observed a significant increase of RRM2
expression in cells with reduced miR-211 expression (Figure 4D).
Discussion
This is the first study evaluating high-resolution profiles of more
than 1200 miRNAs in PDAC patients with homogeneous
clinicopathological characteristics, but extremely differential out-
come (i.e., short vs. long-OS). Unsupervised hierarchical analysis
of the data from this array revealed that PDAC specimens
clustered according to their short/long-OS classification.
Highly stringent statistics identified the top 4 discriminating
miRNAs (miR-211, miR-1207-3p, miR-326 and miR-4321)
between patients with short vs. long-OS, and we performed a
validation of the prognostic role of miR-211, which resulted as the
best discriminative miRNA and of the rarely investigated miR-
4321 in an independent cohort of 60 PDAC. Moreover, we
evaluated the role of miR-211 in the modulation of gemcitabine
activity in chemosensitivity and PCR studies.
These results support further prospective studies to evaluate the
use of miR-211 in risk stratification for resected PDACs.
Although worldwide survival data for PDAC are the lowest
among the 60 most frequent types of organ cancers and careful re-
evaluation of histological specimens is mandatory in order to avoid
misdiagnosis [26], about 20–25% of patients with resectable
PDAC survive for more than 5 years after surgery, suggesting that
some patients have a less aggressive form of disease [27,28].
Therefore, the identification of key determinants for the differen-
tial aggressiveness of PDAC might be used to stratify patients and
guide therapeutic decisions. A multivariate analysis in a case-
control study conducted of 357 patients who underwent pancre-
atoduodenectomy identified lymph node status as the most
relevant prognostic factor for long-term survival among clinico-
pathological characteristics [28]. More recently, a six-gene
signature that discriminated optimally between high-risk (aggres-
sive) and low-risk (less aggressive) tumors on the basis of survival,
was identified using microarrays analysis of gene expression
patterns in primary tumor samples from 15 patients with localized
PDAC and 15 patients with metastatic disease [29]. However, the
comparison of primary PDAC tumors at the extremes of disease
(e.g., early vs. late stage) might not reflect molecular differences in
biology within primary PDAC tumors in the same stage, and the
search for genes of biological significance in large gene expression
datasets is particularly challenging in PDAC.
Therefore, we selected patients with similar clinicopathological
characteristics and treatment, but considerable variation in clinical
outcomes (e.g., patients with dismal prognosis versus patients who
survived more than 30 months). In this unique dataset we
performed an array analysis of miRNA, which gave the advantage
of investigating multiple regulatory networks likely involved in
oncogenic pathways, based on the miRNA ability to target several
genes. Another advantage of miRNAs as biomarkers is that
technological advances have made it possible to reliably determine
their expression using archival FFPE tissues, as also demonstrated
by our successful analysis of most samples. This approach is
logistically more convenient than evaluating gene expression in
frozen tissues, and has relevant implications in studies involving
the pancreas, an organ with high endogenous nuclease activity,
and a very small amount of tumor tissue available [30].
Several previous studies evaluated detailed large-scale profiles of
miRNAs in human PDAC, with a number of studied miRNA
ranging from 95 to 866 [31–32]. Most studies focused on
differences between normal and tumoral pancreatic tissues, or
chronic pancreatitis [33–42]. The results of these studies have
been collected in the PED database, which has established itself as
one of the main repository for pancreatic-derived -omics data.
However, only a few studies evaluated correlation of miRNA
profiles with clinical outcome. In particular, Bloomston and
colleagues [34], using the miRNA microarray chip OSU_CCC
v.3.0, which contains 326 human miRNA probes, identified a
subgroup of six miRNAs (miR-30a-3p, miR-105, miR-127, miR-
187, miR-452, and miR-518a2) that distinguish long-term
survivors with node-positive disease from those succumbing within
24 months. Moreover, grouping the patients according to high or
low expression relative to the mean expression of each miRNA on
the microarray, two miRNAs were predictive of median survival.
High expression of miR-196a-2, which was seen in 75% of tumors,
resulted in 2-year survival of 17% compared with 64% for low
expression (P= 0.009), whereas median survival in patients with
high expression of miR-219 was 13.6 months, compared with 23.8
months for those with low expression, with 2-year survivals of 25%
and 49%, respectively (P = 0.07). None of these miRNAs were
significantly different in our list of miRNAs filtered based on
significant t-test p-value between patients with short/long-OS.
Conversely, the recent study of Jamieson and colleagues [43],
using Agilent’s Human miRNA Microarrays v.2.0, carrying 723
human miRNAs, and a quantitative-PCR method for the
validation in a separate cohort of patients, identified the prognostic
Table 4. Factors associated with OS and DFS in the
multivariate analysis.
Multivariate analysis
Covariates for OS
Hazard ratio
(95%CI) df P
Grading G1–2 0.6 (0.3–1.1) 1 0.11
G3 1 (ref.)
miR-211 expression Low 2.0 (1.1–4.1) 1 0.04
(vs. median) High 1 (ref.)
miR-211 expression #1 2.8 (1.3–5.8) 1 0.006
(clustering) #2 1 (ref.)
Covariates for DFS Hazard ratio (95%CI) df P
Grading G1–2 1 (ref.) 1 0.04
G3 2.23 (1.03–4.85)
miR-211 expression Low 1 (ref.) 1 0.24
(vs. median) High 2.08 (0.61–7.04)
miR-211 expression #1 2.30 (1.16–4.56) 1 0.02
(clustering) #2 1 (ref.)
Abbreviations: df, degrees of freedom; DFS, Disease Free Survival; OS, Overall
Survival.
doi:10.1371/journal.pone.0049145.t004
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value of two miRNAs, miR-21 and miR-34a, that were detected
among the miRNAs significantly different in our patients with
short vs. long-OS. These results are in agreement with several
previous studies, supporting the association of high miR-21
expression with poor OS [12–13,44]. Of note, an additional
analysis of our previous data in 28 PDAC patients treated with
gemcitabine [12], showed that 93% of the patients with high miR-
21 expression had also low expression of the most discriminative
miRNA emerging from the present study, miR-211. Similarly,
90% of the patients with low miR-21 expression had also high
miR-211 expression. Therefore, the survival curves of these
miRNAs had a similar shape (Figure S10).
The proposed oncogenic properties of miR-21 are supported by
its almost ubiquitously expression as well as by several functional
investigations showing that modulation of this miRNA affected
proliferation, invasion and chemosensitivity of cancer cell lines,
including PDAC cells [45–47]. Similarly, preclinical studies in
PDAC cells showed that miR-34 was involved in the reversal of
the tumor suppressing function of p53 in p53-deficient cells, as well
as in pancreatic cancer stem cell self-renewal, potentially via the
direct modulation of downstream targets Bcl-2 and Notch [48].
However, to our knowledge, this is the first study unraveling the
possible prognostic role of miR-211, miR-1207-3p, miR-326 and
miR-4321 in PDAC. MiR-211 is encoded within the sixth intron
of TRPM1, a candidate suppressor of melanoma metastasis [49–
50], and previous researches demonstrated that overexpression of
miR-211 inhibited both anchorage-independent colony formation
and invasion, through regulation of IGF2R, TGFBR2, NFAT5
and BRN2 [51–52]. In contrast, a recent study in the colorectal
cancer cell line HCT-116 showed that miR-211 expression
promotes cellular growth in vitro and in vivo by targeting the tumor
suppressor CHD5 [53], while another study detected an associ-
ation between higher miR-211 expression and the most advanced
nodal metastasis, vascular invasion, and poor prognosis of oral
carcinoma [54]. Finally, a recent TaqMan miRNA array for 365
miRNAs identified 24 miRNAs whose expression was altered in
two gemcitabine resistant pancreatic cancer cell lines, including
the miR-211 homolog miR-204 (sharing the same seed sequence
with miR-211). The following qRT-PCR analyses showed that
radically resected PDAC patients with high miR-204 expression
had significantly longer survival times than those with low
expression (P = 0.0054) expression [55]. However this association
was observed only in the gemcitabine-treated group, supporting
the hypothesis that the prognostic role of mir-204/miR-211 is
possibly tumor specific, as well as treatment-related.
Accordingly, in our in vitro studies, miR-211 overexpression with
a specific pre-miR significantly increased the antiproliferative
effects of gemcitabine, while miR-211 suppression caused a
significant reduction of gemcitabine activity. Of note, the
modulation of miR-211 expression affected the mRNA expression
of the predicted target RRM2. RRM2 is a target of gemcitabine
activity and a previous study correlated RRM2 expression to
Figure 4. In vitro studies validating the role of miR-211 in gemcitabine chemosensitivity. (A) MiR-211 expression in 9 PDAC cell lines and 5
primary tumor cultures. Expression was determined by quantitative PCR, using RNU6 as reference, and the values are in a.u. (B) MiR-211 expression in
MIA PaCa-2 and LPc028 cells transfected with negative controls, pre-miR-21 or anti-miR-21 oligos. MiR-211 expression was calculated with the 22DDCT
method with respect to the expression in cells transfected with negative miRNA controls, set as 1, as represented by the dotted line (C) Gemcitabine
antiproliferative effects in MIA PaCa-2 and LPc028 cells transfected with miRNA negative controls, pre-miR-21 or anti-miR-21 oligos. *Significantly
different from control transfected cells, which were not treated with gemcitabine, set at 100% (P,0.05). (D) RRM2 mRNA expression in MIA PaCa-2
and LPc028 cells transfected with negative controls, pre-miR-21 or anti-miR-21 oligos. RRM2 expression was calculated with the 22DDCT method with
respect to the expression in cells transfected with miRNA negative controls, set as 1, as represented by the dotted line. Columns, mean values
obtained from three independent experiments; bars, SE. *Significantly different from control (P,0.05).
doi:10.1371/journal.pone.0049145.g004
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gemcitabine sensitivity in PDAC cells [25], supporting the
hypothesis that the modulation of gemcitabine sensitivity by
miR-211 might be explained at least in part by the modulation of
RRM2.
A few studies evaluated the potential role of miR-326 in
different cancer types. In particular, this miRNA was downreg-
ulated in a panel of advanced breast cancer tissues and reversely
associated with expression levels of Multidrug resistance associated
protein (MRP-1/ABCC1). Furthermore, elevated levels of miR-
326 in the mimics-transfected MCF VP-16-resistant cells reduced
MRP-1 expression and sensitized these cells to VP-16 and
doxorubicin [56]. Although the impact of ABC transporter family
on pharmacokinetics and pharmacodynamics for gemcitabine still
remains to be defined, a recent study showed that MRP-1/
ABCC1 expression correlated with PDAC tumorigenesis and
gemcitabine resistance [57], potentially explaining why our long-
survivors patients had a significantly higher expression of its
negative regulator miR-326 compared to the patients with short-
OS.
Other studies supported the tumor suppressive activity of
miRNA-326 through targeting of the Notch pathway in glioma
and glioma stem cells [58], as well as its role as suppressor of the
pathway activator Smoothened in the regulatory circuitry of the
Hedgehog (Hh) signaling, suggesting that alterations of this specific
miRNA might sustain cancer development [59]. Notably, the
activation of the Hh pathway plays a key role in the desmoplastic
hypovascular microenvironment which is now recognized to
represent the cardinal histological hallmark feature of PDAC,
creating a ‘fortress-like’ hypovascular barrier that impairs the
delivery of chemotherapeutics and promotes aggressive neoplastic
cell behavior [60]. Therefore, regulation of miR-326 might
represent an innovative appealing target to deplete tumor-
associated stromal tissue acting on the paracrine signalling axis
from neoplastic to stromal cells.
The miR-1207-3p sequence is related to a group of mammalian
miRNAs with overlapping seeds (rno-miR-337, mmu-miR-763,
and hsa-miR-565) and has been recently detected in a panel of
cancer cell lines, during the identification of MiRNAs in the
genomically unstable region of human chromosome 8q24 [61]
that is also frequently alterated, with high copy number gain, in
PDAC [62]. However, no data are available on the possible
biological role of this miRNA in cancer. Similarly, no information
are available for miR-4321, except that it was identified in the
SOLiD ultra-deep sequencing for unique small RNAs from
human embryonic stem cells and neural-restricted precursors that
were fit to a model of microRNA biogenesis to computationally
predict 818 new miRNA genes [63]. However our PCR analysis of
miR-4321 expression in an additional cohort of 60 PDAC patients
did not confirm its correlation with clinical outcome. These
controversial results might be explained by the small sample size,
and/or by the hypothesis that miR-4321 could not predict the
outcome in an average population of PDAC patients (i.e., a
population including both patients with very long/short survival
and patients with a survival between 12 and 30 months).
Future functional studies to validate the predicted targets of our
top miRNAs are warranted. However, a major drawback for
miRNA functional studies is the difficulty in determining the
specific target genes regulated by a given miRNA at the
transcriptional or translational level. The most commonly used
prediction algorithms frequently predict hundreds of target
transcripts for any single miRNA, and it is likely that this high
number contain a significant fraction of false-positive genes.
Therefore, it was not unexpected that the top 4 miRNAs emerging
from our study are predicted by TargetScan and miRDB to
potentially be able to target a total of 1575 and 1242 individual
transcripts, respectively. In order to reduce this high number and
enrich for targets with a potential relevance in PDAC biology, we
performed a comparison among the transcripts targeted by
multiple miRNAs. This approach reduced the TargetScan list of
targets to 169 known transcripts, with 13 transcripts targeted by 3
out of our 4 miRNAs. However, it remains difficult to estimate the
true false-positive rate of current target prediction algorithms, and
the experimental validation of the candidate targets will be an
important next step. The list of candidates identified by our
enrichment strategy represents, combined with published data, a
useful guide for these future studies.
The major strengths of the present study are that it was
performed on a homogeneous setting of patients, whose specimens
have been all carefully reviewed, and were all treated with the
same adjuvant chemotherapy regimen. Moreover, we confirmed
the prognostic role of miR-211 in an appropriate validation
cohort. Since the Toray’s 3D-GeneTM miRNA chip allowed
studying more than 1200 miRNAs, this is the analysis on the
largest number of miRNAs ever performed in PDAC. In order to
focus on the more discriminative miRNAs we used selective
statistical methods with computational analyses performed in the
freely available R programming language.
Conversely, the main limitations included the relatively modest
sample size of the long-OS patients, and the retrospective
explorative single-arm study design. Further studies should
validate our candidate miRNAs in a larger cohort, ideally in the
prospective and multicentre setting. However, the planning of
randomized studies with a control arm of patients treated with
other regimens and the comparison of the survival stratified by
miRNA expression would be the only way to establish their
predictive role. These studies should also establish the potential use
of our candidate miRNAs in the neoadjuvant setting, which might
provide an excellent alternative for patients with very aggressive
disease, who could be given chemotherapy before surgery to kill
any micrometastases. Moreover, to overcome the problems
regarding tissue availability in the different clinical settings, more
accessible samples sources, such as miRNAs enriched tumor
derived exosomes in peripheral blood, should be investigated.
In conclusion, our data provide a strong rationale for future
mechanistic and clinical studies seeking to link prognostically
significant miRNAs, such as miR-211, for their utility as predictive
biomarkers and possible innovative tools for molecular therapies in
the subset of PDAC patients that they define.
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